Selank is described as a heptapeptide - a peptide built from seven amino acids (sequence TKPRPGP). An identity fact, not a Form Labs product claim.
Selank sequence identity (TKPRPGP)Plain-English research guideTP-7 / TKPRPGP
Selank research guide
Everything worth knowing, without the jargon.
Selank is a synthetic heptapeptide (seven amino acids, sequence TKPRPGP; research name TP-7) developed in Russia at the Institute of Molecular Genetics, Russian Academy of Sciences, as a tuftsin analog with a Pro-Gly-Pro tail.
REV 2026-07 · 7 Aug 20265 peer-reviewed studiesResearch-use-only context
What the papers reportThird-party literature - not product claims
The first four amino acids, TKPR, match the tuftsin pattern. A structure record, not a Form Labs product claim.
Koroleva and Myasoedov, Biology Bulletin, 2019Inflammation-related genes with altered activity in mouse spleen in the Kolomin 2011 laboratory study. A mouse-tissue finding, not a Form Labs product claim.
Kolomin et al., Regulatory Peptides, 2011Why it matters
Mostly animal and laboratory research, plus Russian clinical records.
Selank was developed in Russia at the Institute of Molecular Genetics, Russian Academy of Sciences, as a synthetic analog of tuftsin. Tuftsin is a short immune-signalling peptide with the sequence TKPR; Selank keeps that four-amino-acid start and adds a Pro-Gly-Pro tail for stability, giving the seven-amino-acid sequence TKPRPGP.
The evidence base looks different from a Western drug-development programme. It includes Russian clinical literature in anxiety-related disorders, animal and cell work on GABA and monoamine systems, immune-marker papers on cytokines and inflammation genes, and biochemical enzyme studies. This guide treats those records as research context only, not as product claims or use guidance.
How it works
One short peptide, several signalling systems.
A plain-English look at each pathway, kept at a summary level.
TKPRPGP identity
Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP, is the seven-amino-acid sequence that identifies Selank in the research. TP-7 is another research name for the same peptide.
Tuftsin analog lineage
Tuftsin is the four-amino-acid sequence Thr-Lys-Pro-Arg, written TKPR. Selank keeps those first four amino acids and adds a Pro-Gly-Pro tail, which the literature describes as a stability-related design feature.
Marker systems, not outcome promises
The cited papers discuss GABA-related binding, monoamine and BDNF marker context, cytokines such as IL-6, inflammation-gene expression, and enkephalin-degrading enzymes. Those are study markers and lab systems, not claims about effects in people.
Pharmacology at a glance
- Research code
- TKPRPGP (TP-7)
- Class
- Synthetic tuftsin analog - the first four amino acids match tuftsin (TKPR), with a Pro-Gly-Pro tail added for stability.
- Molecule
- A synthetic heptapeptide (seven amino acids). CAS 129954-34-3, molecular formula C33H57N11O9, molecular weight about 751.9 g/mol.
- Route studied
- Published Selank records include clinical and laboratory study contexts. This field is study-record context only, not route, preparation, or dosing guidance; Form Labs gives no route, preparation, or dosing guidance for the material it supplies.
- Reported half-life
- No clean pharmacological half-life is quoted here. The literature instead discusses structure-stability design and biochemical enzyme context, including enkephalin-degrading enzymes in human serum.
- Originator
- Institute of Molecular Genetics, Russian Academy of Sciences (Russia)
- Approval status
- developed and used in Russia as an anxiolytic and sold in Russian pharmacies, but not approved by the TGA (Australia) or the FDA (US), and no marketing authorisation in the EU.
What it has been studied for
Study areas from the published literature.
Anxiety-related behaviour and clinical scales
Studied in a Russian clinical record in generalized anxiety disorder and neurasthenia, tracking psychometric scales and serum enkephalin activity.
Zozulya et al., Zhurnal Nevrologii i Psikhiatrii, 2008Immune and cytokine markers
Studied for immune-marker context, including IL-6, T-helper cytokine balance, IFN-alpha context, and inflammation-related gene expression.
Uchakina et al., Zhurnal Nevrologii i Psikhiatrii, 2008; Kolomin et al., Regulatory Peptides, 2011GABA and monoamine systems
Studied for GABA ligand-receptor interaction and neurotransmission-gene context in laboratory and animal models.
Vyunova et al., Neurochemical Journal, 2014; Volkova et al., Frontiers in Pharmacology, 2016BDNF marker context
Discussed in Selank physiology literature as part of nerve-growth-marker context; this guide does not quote a standalone human BDNF outcome.
Koroleva and Myasoedov, Biology Bulletin, 2019Enkephalin-degrading enzymes
Studied for inhibition of enkephalin-degrading enzymes in human serum, a biochemical context rather than a product-effect claim.
Kost et al., Russian Journal of Bioorganic Chemistry, 2001The studies
The evidence, study by study.
Open any study for a plain summary, what it measured, the finding, and a link to the paper.
A 14-day Russian clinical study comparing intranasal Selank with medazepam in 62 patients with generalized anxiety disorder or neurasthenia.
- Studied in
- 62 patients with generalized anxiety disorder or neurasthenia.
- Design
- A 14-day clinical comparison record: intranasal Selank group 30 patients, medazepam group 32 patients.
- Measured
- Psychometric scales and serum enkephalin activity.
This is the human-research anchor for Selank in the Russian literature. It records a study population, comparator, scales, and serum enkephalin activity, but this guide draws no efficacy conclusion from it and does not treat it as a Western regulatory trial.
DOI https://pubmed.ncbi.nlm.nih.gov/18454096/A rat frontal-cortex study measuring expression of neurotransmission-related genes after Selank exposure.
- Studied in
- Rat frontal cortex.
- Design
- A preclinical gene-expression study focused on 84 neurotransmission-related genes.
- Measured
- GABAergic and monoamine-related gene-expression context.
The study reported changes in neurotransmission-related gene activity in rat brain tissue. This is an animal laboratory record, not a claim about mood, anxiety, cognition, or any person.
DOI 10.3389/fphar.2016.00031A laboratory study of Selank in GABA ligand-receptor interaction with nerve-cell plasma membranes.
- Studied in
- Nerve-cell plasma membrane preparations.
- Design
- A receptor-interaction and binding study.
- Measured
- GABA ligand-receptor interaction and binding context.
The paper is included as a narrow GABA receptor-binding record. It is not a claim that Selank changes anxiety, mood, or cognition in people.
DOI 10.1134/S1819712414040114A mouse-spleen study measuring inflammation-related gene expression after Selank in an IFN-alpha context.
- Studied in
- Mouse spleen tissue.
- Design
- A laboratory gene-expression study of 84 inflammation-related genes.
- Measured
- Number and identity of inflammation-related genes with altered activity.
The study reported 34 of 84 inflammation-related genes with altered activity in mouse spleen. This is a mouse-tissue laboratory finding, not a Form Labs product claim.
DOI 10.1016/j.regpep.2011.05.001A biochemical study measuring how Semax and Selank interact with enkephalin-degrading enzymes of human serum.
- Studied in
- Human serum enzyme assays.
- Design
- An in-vitro biochemical enzyme study.
- Measured
- Inhibition of enkephalin-degrading enzymes.
The paper reported that Semax and Selank inhibit enkephalin-degrading enzymes in human serum. This is biochemical context, not a claim about what the Form Labs material does in a person.
DOI 10.1023/A:1011373002885Where evidence stops
Groups and questions not established.
- Large Western clinical trials: there is no Phase 1-3 programme reviewed by the TGA, FDA, or EU regulators.
- Any use in or on people or animals: none of the research on this page is a use direction.
- What a specific batch does: the studies are about the molecule in general, not this vial.
- Preparation, dosing, or administration: not covered here. Form Labs gives no such guidance.
Development and status
Where the research record sits.
Selank is developed at the Institute of Molecular Genetics, Russian Academy of Sciences, as a synthetic tuftsin analog with a Pro-Gly-Pro tail.
Kost and colleagues report biochemical work on Semax and Selank inhibiting enkephalin-degrading enzymes in human serum.
Zozulya and colleagues publish a Russian clinical study record in 62 patients with generalized anxiety disorder or neurasthenia.
Uchakina and colleagues publish immune-marker context for IL-6 and T-helper cytokine balance in anxiety-asthenic disorders.
Kolomin and colleagues report 34 of 84 inflammation-related genes altered in mouse spleen in a Regulatory Peptides study.
Vyunova and colleagues publish GABA ligand-receptor interaction work in Neurochemical Journal.
Volkova and colleagues publish rat frontal-cortex gene-expression work in Frontiers in Pharmacology.
Koroleva and Myasoedov publish a Biology Bulletin review covering Selank structure and physiology context.
Approval status: developed and used in Russia as an anxiolytic and sold in Russian pharmacies, but not approved by the TGA (Australia) or the FDA (US), and no marketing authorisation in the EU.Whatever the molecule’s status elsewhere, what Form Labs supplies is research-use-only reference material - for laboratory work, not for people or animals.
Evidence and limitations
What this means, and what it does not.
Mostly animal and laboratory research, plus Russian clinical literature
Most of the Selank evidence base is animal, cell, immune-marker, and biochemical work. The human anchor is Russian clinical literature in anxiety-related disorders, not a Western drug-development programme.
No TGA or FDA approval, no EU marketing authorisation
Selank was developed and used in Russia as an anxiolytic and sold in Russian pharmacies, but it is not approved by the TGA (Australia) or the FDA (US), and it has no marketing authorisation in the EU. Nothing here should be read as Western regulatory approval.
The 62-patient record is not an efficacy claim
The Zozulya study gives the human-study size and comparator context for the literature record. This guide does not turn that record into a claim that Selank treats anxiety-related disorders or changes mood in people.
No dosing or use guidance
This guide does not provide preparation, dosing, administration, or use instructions of any kind. It is a plain summary of published research, not a protocol.
Where Form Labs fits
This guide is a plain-English summary of published research that Form Labs did not run. It is not medical advice, not a product claim, and not use guidance. Form Labs supplies Selank strictly as reference material, with a batch number that can be matched to its lab report, for laboratory research.
Lab handling
Reference-material handling context.
Research-use boundary
Selank is supplied strictly for laboratory research. It is not for human, veterinary, medical, cosmetic, or any other use, and no directions for use are given.
COA and label
The certificate of analysis (COA) and vial label are the authority for identity, purity, appearance, and release for the batch. The batch or lot number should match the account-delivered lab report.
Storage
Supplied freeze-dried. Keep it at 2-8°C (fridge-cold) and out of light, following the vial label, the matching lab report for the batch, and the receiving lab's own written procedures.
Stability
Selank is described as a tuftsin analog with a Pro-Gly-Pro tail for stability, but this guide does not set a reconstitution method or working window. Those decisions belong in the receiving lab's own written protocol and batch paperwork.
Glossary
Plain-English definitions.
- Heptapeptide
- A peptide made from seven amino acids; Selank's sequence is TKPRPGP.
- TP-7
- A research name used for Selank in the literature.
- Tuftsin
- A natural four-amino-acid peptide with the sequence Thr-Lys-Pro-Arg, written TKPR.
- Tuftsin analog
- A lab-made peptide designed around tuftsin's sequence pattern; Selank keeps TKPR and adds Pro-Gly-Pro.
- Pro-Gly-Pro tail
- The final three amino acids in Selank's sequence, described in the literature as a stability-related tail.
- BDNF
- Brain-derived neurotrophic factor - a protein researchers measure as a nerve-growth marker.
- GABA
- A signalling molecule named here only in receptor-interaction and neurotransmission-gene research.
- Monoamine
- A group of signalling chemicals that includes dopamine and serotonin.
- Cytokine
- An immune-system signalling protein measured in some Selank immune-marker papers.
- Research use only (RUO)
- A lab-only boundary: not for human consumption, veterinary, medical, or cosmetic use.
FAQ
Questions answered plainly.
Selank is a synthetic heptapeptide (a seven-amino-acid peptide) with the sequence TKPRPGP, developed in Russia at the Institute of Molecular Genetics as an analog of the natural peptide tuftsin. It is studied in published research for its role in anxiety-related behaviour and immune-marker (cytokine) systems, mostly in animal studies plus some Russian clinical research. Form Labs supplies Selank strictly as research-use-only reference material, not for human or veterinary use.
Selank's sequence is TKPRPGP (Thr-Lys-Pro-Arg-Pro-Gly-Pro), a synthetic heptapeptide built as an analog of tuftsin. The first four amino acids match the tuftsin fragment (Thr-Lys-Pro-Arg), and a Pro-Gly-Pro tail is added to make the peptide more stable. It is also indexed in research as TP-7. Its chemical registry number is CAS 129954-34-3, molecular formula C33H57N11O9, molecular weight about 751.9 g/mol.
Selank is studied in research for anxiety-related behaviour, BDNF marker context, immune and cytokine markers, GABA-related binding, and serotonin or monoamine systems. The cited records are mostly animal, cell, immune-marker, and biochemical studies, plus Russian clinical literature. Those records are research context only, not Form Labs product claims or use guidance.
Selank is often described in popular writing with anxiolytic or nootropic labels, but those labels refer to how it is discussed and regulated in some contexts, not to anything Form Labs is claiming. In the published research it is studied for anxiety-related behaviour and immune-marker experiments, mostly in animal models plus some Russian clinical work. Form Labs supplies Selank strictly as research-use-only reference material, and nothing on this page is a claim of anxiety, mood, or cognitive effects in people.
Selank and Semax are two different synthetic peptides. Selank is the sequence TKPRPGP, an analog of the peptide tuftsin, and is studied more in anxiety- and immune-marker research; Semax is the sequence MEHFPGP, an analog of a fragment of the hormone ACTH, and is studied mostly in neuroprotection and cognition research. Form Labs supplies both only as research-use-only reference material.
Selank is a tuftsin analog, meaning its first four amino acids match tuftsin's TKPR sequence and the peptide adds a Pro-Gly-Pro tail. Published research discusses BDNF as a nerve-growth marker and immune-marker systems including IL-6, T-helper cytokine balance, IFN-alpha context, and inflammation-gene expression. Those are laboratory and literature measurements, not claims about effects in people.
Selank is developed and used in Russia as an anxiolytic and is sold in Russian pharmacies, but it is not approved by the Therapeutic Goods Administration (TGA) in Australia or the FDA in the United States, and it has no marketing authorisation in the European Union. Form Labs supplies it only as research-use-only reference material, not as a medicine and not for human or veterinary use.
Selank is supplied by Form Labs in Australia as research-use-only reference material, not as a medicine and not for human or veterinary use. This guide is not legal advice or scheduling advice, and availability as research material should not be read as TGA approval. Researchers should rely on their own compliance procedures for lawful handling and procurement.
Selank is supplied strictly as laboratory research material. This guide is a plain-English summary of published research that Form Labs did not run - not medical advice, not a product claim, and not guidance for any human or veterinary use.
Selank is supplied freeze-dried, and the handling notes call for storage at 2-8°C (fridge-cold), protected from light, with the vial label matched to the COA for the batch such as lot SELANK-2506 where shown. Orders use Form Labs' standard bank-transfer prepay flow. Shipping is AU-only from Perth via Australia Post: $10 standard (5-7 days) or $20 Express (2-3 business days), with standard shipping free on orders of $250 or more. Express is always charged. Tracking is emailed when the parcel is lodged.
References
Every figure, sourced.
Educational references to third-party literature. Form Labs is unaffiliated with the study authors.
Zozulya AA et al. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova, 2008 - 62 patients with generalized anxiety disorder or neurasthenia; Selank 30 versus medazepam 32; psychometric scales and serum enkephalin activity. PMID 18454096.
Uchakina ON et al. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova, 2008 - IL-6 and Th1/Th2 cytokine-balance context in anxiety-asthenic disorders. PMID 18577961.
Kolomin TA et al. Regulatory Peptides, 2011, 170(1-3):18-23 - mouse-spleen study of 84 inflammation genes, with 34 changed.
DOIVolkova A et al. Frontiers in Pharmacology, 2016, 7:31 - rat frontal-cortex study of 84 neurotransmission genes in GABAergic and monoamine context.
DOIVyunova TV et al. Neurochemical Journal, 2014, 8:259-264 - GABA ligand-receptor interaction and binding with nerve-cell plasma membranes.
DOIKost NV et al. Russian Journal of Bioorganic Chemistry, 2001, 27:156-159 - Semax and Selank inhibition of enkephalin-degrading enzymes of human serum.
DOIKoroleva SV and Myasoedov NF. Biology Bulletin, 2019, 46:407-414 - Selank structure and physiology review; general background context.
DOICitations are provided for education only. No therapeutic, weight-loss, or efficacy claims are made.
How we produce these guides
- Who writes them
- These guides are written and maintained in-house by the Form Laboratories research team. They are not authored by a named clinician, and nothing in them is medical advice. Where a guide is short, that is because the published research is thin - we would rather say so than fill the space.
- What they are built from
- Each guide summarises published, peer-reviewed literature. Every study we describe is listed in full at the bottom of the page with a link to the original paper, so you can open it and check what it actually says. Form Laboratories did not run any of the cited studies.
- What they deliberately leave out
- These guides describe how the biology works and what the published research measured. They do not contain dosing, preparation, reconstitution or administration instructions, and they make no claim about what any compound would do for a person. Everything we supply is research-use-only reference material.
- How we handle uncertainty
- Where the evidence is limited to cell cultures or animals, we say so in the study entry rather than implying a human result. Where a compound has no completed human trial, the guide states that plainly.
The product
Form Laboratories - Selank
Ready to see Selank?
- Independently tested - purity printed on the lab report.
- A batch number on every vial, matched to its report.
- Ships from Perth via Australia Post in plain packaging.
Build your stack
Compare nearby catalogue records.
These nearby records stay inside the research-only catalogue.
Research-use-only catalogue
Continue to the product record.
Review lot-facing product details, pricing, and checkout boundaries on the matching product page.
View Selank - from $99.00 AUD